Cart
sales@molnova.com
Retatrutide
CAS No. 2381089-83-2
Retatrutide( —— )
Catalog No. M36652 CAS No. 2381089-83-2
Retatrutide (LY3437943) is a triple agonist of the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor (GLP-1R), and inhibits GCGR, GIPR, and GLP-1R.Retatrutide can be used to study obesity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 591 | In Stock |
|
| 10MG | 947 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameRetatrutide
-
NoteResearch use only, not for human use.
-
Brief DescriptionRetatrutide (LY3437943) is a triple agonist of the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor (GLP-1R), and inhibits GCGR, GIPR, and GLP-1R.Retatrutide can be used to study obesity.
-
DescriptionRetatrutide (LY3437943) is a triple agonist peptide of the glucagon receptor (GCGR), glucosedependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Retatrutide binds human GCGR, GIPR, and GLP-1R with EC50 values of 5.79, 0.0643 and 0.775 nM, respectively. Retatrutide can be used for the research of obesity.
-
In Vitro——
-
In VivoAnimal Model:Diet-induced obese (DIO) male C57/Bl6 mice (24-25 weeks, 40-51 g) Dosage:10 mL/kg Administration:Subcutaneous (SC) injection, cycle every 3 days, for 21 days Result:Decreased body weight and improved glycemic control.
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGlucagon Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2381089-83-2
-
Formula Weight4731.33
-
Molecular FormulaC221H342N46O68
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (10.57 mM; Ultrasonic ) H2O : 33.33 mg/mL (7.04 mM; ultrasonic and adjust pH to 7 with NaOH)
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Tamer Coskun, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022 Sep 6;34(9):1234-1247.e9.?
molnova catalog
related products
-
MK-0893
A potent, selective, reversible and competitive antagonist of glucagon receptor with high binding affinity (IC(=50=6.6 nM) and functional cAMP activity (IC50=15.7 nM).
-
PF-06882961
PF-06882961 is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06882961 shows mild to moderate damage to the heart, moderate to severe effects on the thymus gland (which helps with managing infection), mild to moderate stomach ulcers at the highest dose level given in the rat.
-
(S, R)-LSN 3318839
(S, R)-LSN 3318839 is an allosteric modulator of the glucagon-like peptide-3318839 receptor (GLP-1R) that has demonstrated powerful hypoglycemic effects in animal models alone or in combination with sitagliptin.
